Its main aim is to bring buyer zeal credit union supplier communities together, via a single portal, providing authentication, secure access and encrypted electronic data transmission. The solution service has been developed by Intenda (Pty) Ltd, authors of the Proqure, eRS, Proquote and other business-to-business e-sourcing solutions. The Proqure system caters for all electronic options, without compromising the standard non-electronic credlt mediums (paper, fax, delivery etc. ) An ERFx is the term used to describe an electronic request for: quotations, tenders, pricing, information and proposals. ERFx notification is available capital one branches near me selecting the Tender Bulletin Service.
Business Strategy We will continue to broaden our product portfolio, develop and implement the optimal risk/reward profile for each product candidate with the clear goal of becoming a highly successful speciality pharmaceutical company. Key elements of our strategy include: Develop improved, proprietary versions of currently marketed drugs We are focusing our product development and commercialisation resources on creating new best-in-class versions of existing drugs in large therapeutic categories such as cardiovascular disease and immunosuppression, such as we have done with LCP-FenoChol and LCP-Tacro. Best-in-class / Improved versions of marketed drugs.
Independent studies have shown that approximately 30% of existing drugs suffer from absorption problems due to low water solubility. We believe that a large number of these drugs may be suitable candidates for our MeltDose® technology, which we intend to use to create new best-in-class versions of these existing drugs. In addition, to expand the range of our proprietary product candidate opportunities we intend to combine our MeltDose® improved products with other marketed drugs to develop combination products with synergistic effects. We intend to selectively pursue a strategy for generic products by developing selective generic versions of marketed drugs when we find that our MeltDose® technology offers a unique opportunity to develop a patented product that is bioequivalent to an existing approved drug, such as we have done with LCP-Feno.